Synthetically produced, human lysosomal protein

Bexion Pharmaceuticals is focused on developing innovative therapies for oncology and central nervous system (CNS) disorders, with its lead compound, BXQ-350, demonstrating promising potential. BXQ-350 operates through multiple mechanisms, primarily by modulating bioactive sphingolipids such as ceramide and sphingosine-1-phosphate (S1P). The compound reduces S1P levels, which are associated with cancer cell proliferation and immunosuppression, while simultaneously increasing ceramide levels that promote programmed cell death in cancer cells. This dual action not only targets tumor cells selectively but also enhances the safety profile of BXQ-350, making it a compelling candidate for treating conditions like metastatic colorectal cancer and chemotherapy-induced peripheral neuropathy (CIPN).

Bexion's clinical development strategy includes a robust pipeline of clinical trials aimed at evaluating the safety and efficacy of BXQ-350 across various patient populations, including those with advanced solid tumors and pediatric brain cancers such as diffuse intrinsic pontine glioma (DIPG). The company has received Orphan Drug status for BXQ-350, which facilitates expedited development and regulatory processes. Early clinical results indicate that BXQ-350 may not only provide anti-tumor activity but also offer neuroprotective benefits, addressing significant unmet needs in cancer treatment and improving the quality of life for patients suffering from debilitating side effects of conventional therapies.

United States

Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS. The company’s lead compound, BXQ-350, is a novel S1P modulator. With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company.

Bexion Pharmaceuticals

Company Details